Annual Conference

Investor perspective: Regulatory developments in the EU, US, UK, China, Japan, … Update on Biopharma investor ESG communications Initiative Key developments and concepts: Double materiality, EU Social Taxonomy, Impact

Privacy, Human Rights, new technologies Diversity, equity, and Inclusion (DE&I) After the crisis: Regulators strike back Legal vs. legitimate

ESG integration is the new normal — What investors expect now Disclosure strategy and internal collaboration across functional areas Best practice within and beyond biopharma

Hard and soft regulatory developments in key regions, especially the EU Biopharma sector response